MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2022.2140569

Медицинская библиотека · The Journal of dermatological treatment · 2023

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.

Ruda Rachel C, Kelly Katherine A, Feldman Steven R

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Tumor necrosis factor (TNF) inhibitors improved clinical outcomes for patients with psoriasis but are limited by their high cost. There are several biosimilar options approved for the treatment of psoriasis which provides a lower-cost alternative and the potential to increase treatment availability for both biologically naïve and bioexperienced patients. Numerous phase III randomized controlled trials (RCTs) have investigated the effects of switching from biologics to biosimilars; biosimilars had comparable safety and efficacy to their reference products. Real-world evidence may provide complementary information on the expected performance of biosimilars. In this literature review, we analyzed data from real-world studies on switching from biologics for psoriasis to their biosimilars. Effectiveness and safety profiles were comparable when switching from biologics to biosimilars of adalimumab, etanercept, and infliximab. These studies are limited by their sample sizes, duration of follow-up, and single-arm designs without control groups. Based on available real-world evidence, patients may safely and effectively undergo switching to biosimilar therapies for the treatment of psoriasis.

Для цитирования: Ruda Rachel C, Kelly Katherine A, Feldman Steven R. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.. The Journal of dermatological treatment. 2023. DOI: 10.1080/09546634.2022.2140569.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.